Legal Insights

Page 3 of 16. Practical M&A and securities guidance from deal counsel.

401(k) Plan Integration After an Acquisition

A detailed legal analysis of 401(k) plan integration strategies following an acquisition: plan merger, freeze, and pre-closing termination; anti-cutback rules under IRC 411(d)(6); the same-desk rule and Rev. Rul. 2002-42; successor plan rule; distributable events; Roth balances; participant loans; blackout periods; SOX 306; nondiscrimination testing; and 5500 audit obligations.

Apr 18, 2026

ADR, RevPAR, FF&E Reserve, and PIP Diligence in Hotel M&A

A detailed legal and operational guide to hotel M&A diligence: ADR, RevPAR, GOPPAR benchmarking, STR and Kalibri Labs data, FF&E reserve adequacy, PIP cost scoping, ADA compliance, environmental review, labor audit, and technology stack assessment.

Apr 18, 2026

Cannabis Management Services Agreements and Brand Licenses

A detailed legal analysis of cannabis Management Services Agreements (MSA), brand licensing mechanics, fee structure variance across states, ownership and control triggers, alternative investment vehicles, convertible notes, call options, holding company strategies, cross-jurisdiction MSO expansion, SEC securities implications, and 280E tax considerations for non-plant-touching cannabis participation.

Apr 18, 2026

Cannabis License Transfers and Change-of-Ownership Rules

A detailed legal analysis of cannabis state license transfers and change-of-ownership approvals: transferable vs. non-transferable regimes, direct transfer vs. entity acquisition, beneficial ownership thresholds, suitability review, pre-approval operating restrictions, interim operating agreements, local jurisdiction consents, community benefit plans, and regulatory reverse termination fees across CA, CO, IL, NY, NJ, FL, MI, NV, MA, OH, and AZ.

Apr 18, 2026

CERCLA Environmental Liability Allocation in Waste M&A

A detailed legal analysis of CERCLA 42 USC 9607 PRP liability in waste management acquisitions: joint and several liability, BFPP defenses, AAI Phase I ESA standards, PFAS designation, RCRA corrective action, state Superfund programs, RWI exclusions, and environmental insurance structures.

Apr 18, 2026

CFIUS Mandatory Declaration Filings for TID Businesses

A detailed legal analysis of CFIUS mandatory declaration requirements for TID businesses: the two filing triggers, TID business identification under critical technology, critical infrastructure, and sensitive personal data criteria, declaration content, the 30-day review clock, no-action letters, penalty exposure for failure to file, and excepted investor exclusions.

Apr 18, 2026

CFIUS Mitigation Agreements: NSAs and Proxy Boards

A detailed legal analysis of CFIUS mitigation agreements in M&A: National Security Agreements, Security Control Agreements, Proxy Agreements, Voting Trusts, Board Resolutions, monitor and auditor roles, FOCI coordination, breach consequences, and how mitigation reshapes deal value.

Apr 18, 2026

CFIUS Real Estate Jurisdiction: 31 CFR Part 802

A detailed legal analysis of CFIUS jurisdiction over real estate under 31 CFR Part 802: covered real estate definitions, proximity zones, Appendix A installations, property rights triggering review, excepted transactions, urbanized area and private residence exceptions, REIT structures, data center overlaps, voluntary filing strategy, and 2024 regulatory amendments.

Apr 18, 2026

CIC Bonus, Severance & Retention in M&A | Acquisition Stars

A detailed legal analysis of CIC severance, retention agreements, and transaction bonuses in M&A: single vs double trigger, good reason and cause definitions, severance tiers, 409A short-term deferral, 280G allocation, working capital treatment of comp liabilities, and post-closing plan integration.

Apr 18, 2026

Clinical Trial Diligence and IND/CTA Transfer in M&A

A detailed legal analysis of clinical trial diligence in pharma M&A: IND sponsor transfer, CTA assignment, TMF review, protocol integrity, IRB re-approval, adverse event reporting continuity, and investigator agreement assumption.

Apr 18, 2026

Contingent Value Rights (CVR) in Pharmaceutical M&A

A detailed legal analysis of contingent value rights in pharma M&A: regulatory and sales milestone triggers, commercially reasonable efforts obligations, tax treatment, SEC registration, CVR trustee duties, and litigation risk under Delaware law.

Apr 18, 2026

Credit Bidding Rights Under Section 363(k)

A detailed legal analysis of Section 363(k) credit bidding rights: the statutory right to bid up to face value, cause-based limitations, Philadelphia Newspapers and Fisker cap doctrine, RadLAX Supreme Court ruling, loan-to-own strategies, syndicated loan coordination, intercreditor conflicts, second lien rights, deficiency claims, tax consequences, sub rosa plan concerns, and good faith requirements under Section 363(m).

Apr 18, 2026

Cybersecurity Reps and Warranties in M&A

A detailed legal analysis of cyber and data privacy representations and warranties in M&A: standard cyber reps, data privacy reps, materiality and knowledge qualifiers, survival periods, indemnity caps and baskets, escrow sizing for cyber exposure, R&W insurance scope and exclusions, disclosure schedule discipline, and coordination of cyber insurance with the indemnity stack.

Apr 18, 2026

Data Privacy Diligence in M&A: GDPR and CCPA Risks

A detailed legal analysis of data privacy diligence in M&A transactions: scoping controller and processor relationships, data mapping, GDPR lawful basis, EU-to-US transfers under SCCs and the Data Privacy Framework, Schrems II DTIAs, CCPA/CPRA and state privacy patchwork, HIPAA, GLBA, COPPA, BIPA, DPA vendor flow-downs, ad-tech diligence, post-close privacy notice integration, breach notification timelines, and remediation planning.

Apr 18, 2026

Distressed M&A and Section 363 Bankruptcy Sales: Legal Guide

A comprehensive legal guide to distressed M&A and Section 363 bankruptcy sales covering the automatic stay, stalking horse bidder mechanics, break-up fees, credit bidding, free and clear sale orders, successor liability, executory contract assumption, Section 1113 CBA treatment, environmental liabilities, 363(m) finality, and committee participation.

Apr 18, 2026

Energy and Oil & Gas M&A: Legal Guide | Acquisition Stars

A comprehensive legal guide to energy and oil & gas M&A: upstream asset transfers, mineral interest conveyance, joint operating agreement assignments, preferential rights and tag-along rights, FERC approval of pipeline and storage transactions, SEC reserves reporting diligence, BOEM offshore lease transfers, and state oil and gas commission notifications.

Apr 18, 2026

Equity Rollover and Section 83 Election Planning in M&A

A detailed legal analysis of equity rollover, Section 83(b) and 83(i) election planning in M&A transactions: continuity of interest, PE rollover mechanics, profits interest vs capital interest, 83(b) for nonvested stock, 83(i) for private company employees, ISO/NQSO treatment, QSBS preservation, parachute payment coordination, and liquidity rights for rolled holders.

Apr 18, 2026

ESOP Target Diligence: Adequate Consideration in M&A

A legal analysis of ESOP target diligence in M&A: ERISA 408(e) prohibited transaction framework, adequate consideration, independent trustee fiduciary process, valuation discipline, DOL process agreements, repurchase obligations, S-corp ESOP planning, 1042 rollover, leverage formulas, post-closing termination, and R&W insurance structuring.

Apr 18, 2026

Considering a Transaction?

We engage selectively with clients who value thorough counsel. Senior attorney Alex Lubyansky works directly on every matter.